Median Technologies Announces the Drawdown of €8.5m Corresponding to the Final Tranche of the European Investment Bank Loan
27 Dicembre 2023 - 5:45PM
Business Wire
Regulatory News:
Median Technologies (Paris:ALMDT) announces that it has received
approval from the European Investment Bank to draw down the final
tranche of the loan granted on December 18, 2019, and renegotiated
at the end of 2022.
The final tranche of €8.5m will be disbursed early January 2024.
This financing has a maturity of five years and bears interest at
5% capitalized. Median has simultaneously issued 300,000 warrants,
at an exercise price of €4.465, with an expiry date in 2035.
" Tranche B of the EIB's €8.5m financing will enable us to
continue our investment plan for eyonis™1 and its early
cancer diagnosis programs. Combined with our other fundings of
2023, this transaction strengthens our financial visibility and
extends our cash flow horizon to the first half of 2025," said
Fredrik Brag, CEO, and founder of Median. "Median Technologies is a
world leader in the development of AI-based medical imaging
solutions. These solutions are revolutionizing patient diagnosis,
treatment, and survival, as well as the development of new cancer
therapies. Whereas the impact of AI is a daily subject of
discussion and is often much feared, in our sector, AI is set to
have a colossal impact on saving patients' lives. In 2023, Median
continued to develop its solutions for patient care and drug
development, and these initiatives will continue to fuel our
newsflow in the first half of 2024, and beyond”, he adds.
About Median Technologies: Median Technologies provides
innovative imaging solutions and services to advance healthcare for
everyone. We harness the power of medical images by using the most
advanced Artificial Intelligence technologies, to increase the
accuracy of diagnosis and treatment of many cancers and other
metabolic diseases at their earliest stages and provide insights
into novel therapies for patients. Our iCRO solutions for medical
image analysis and management in oncology trials and eyonis™, our
AI/ML tech-based suite of software as medical devices (SaMD), help
biopharmaceutical companies and clinicians to bring new treatments
and diagnose patients earlier and more accurately. This is how we
are helping to create a healthier world.
Founded in 2002, based in Sophia-Antipolis, France, with a
subsidiary in the US and another one in Shanghai, Median has
received the label “Innovative company” by the BPI and is listed on
Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median
is eligible for the French SME equity savings plan scheme
(PEA-PME). For more information: www.mediantechnologies.com
_____________
1 Formerly known as iBiopsy®.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231227390108/en/
Median Technologies Emmanuelle Leygues Head of Corporate
Marketing & Financial Communications +33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com
Press - ALIZE RP Caroline Carmagnol +33 6 64 18 99 59
median@alizerp.com
Investors - ACTIFIN Ghislaine Gasparetto +33 6 21 10 49
24 ggasparetto@actifin.fr
Grafico Azioni Median Technologies (EU:ALMDT)
Storico
Da Feb 2025 a Mar 2025
Grafico Azioni Median Technologies (EU:ALMDT)
Storico
Da Mar 2024 a Mar 2025
